Home
/
Metagenomi Therapeutics, Inc.
/
Financials
/
Quarterly
Metagenomi Therapeutics, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Metagenomi Therapeutics, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$8.66M
Nov 12, 2025
Q2
2025
Jun 30, 2025
$8.51M
Aug 12, 2025
Q1
2025
Mar 31, 2025
$4.13M
May 13, 2025
Q3
2025
Sep 30, 2024
$11.51M
Nov 12, 2025
Q2
2025
Jun 30, 2024
$20.01M
Aug 12, 2025
Q1
2025
Mar 31, 2024
$11.16M
May 13, 2025
Q3
2024
Sep 30, 2023
$12.36M
Nov 13, 2024
Q2
2024
Jun 30, 2023
$11.34M
Aug 14, 2024
Q1
2024
Mar 31, 2023
$8.66M
May 14, 2024
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($20.39M)
Nov 12, 2025
Q2
2025
Jun 30, 2025
($19.91M)
Aug 12, 2025
Q3
2025
Jun 30, 2025
($19.91M)
Nov 12, 2025
Q3
2025
Mar 31, 2025
($25.04M)
Nov 12, 2025
Q2
2025
Mar 31, 2025
($25.04M)
Aug 12, 2025
Q1
2025
Mar 31, 2025
($25.04M)
May 13, 2025
Q3
2025
Sep 30, 2024
($18.77M)
Nov 12, 2025
Q2
2025
Jun 30, 2024
($10.74M)
Aug 12, 2025
Q3
2025
Jun 30, 2024
($10.74M)
Nov 12, 2025
Q3
2025
Mar 31, 2024
($25.15M)
Nov 12, 2025
Q2
2025
Mar 31, 2024
($25.15M)
Aug 12, 2025
Q1
2025
Mar 31, 2024
($25.15M)
May 13, 2025
Q3
2024
Sep 30, 2023
($19.82M)
Nov 13, 2024
Q2
2024
Jun 30, 2023
($13.01M)
Aug 14, 2024
Q3
2024
Jun 30, 2023
($13.01M)
Nov 13, 2024
Q2
2024
Mar 31, 2023
($16.13M)
Aug 14, 2024
Q3
2024
Mar 31, 2023
($16.13M)
Nov 13, 2024
Q1
2024
Mar 31, 2023
($16.13M)
May 14, 2024
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($22.84M)
Nov 12, 2025
Q2
2025
Jun 30, 2025
($20.99M)
Aug 12, 2025
Q1
2025
Mar 31, 2025
($27.82M)
May 13, 2025
Q3
2025
Sep 30, 2024
($22.38M)
Nov 12, 2025
Q2
2025
Jun 30, 2024
($16.86M)
Aug 12, 2025
Q1
2025
Mar 31, 2024
($29.03M)
May 13, 2025
Q3
2024
Sep 30, 2023
($22.40M)
Nov 13, 2024
Q2
2024
Jun 30, 2023
($17.96M)
Aug 14, 2024
Q1
2024
Mar 31, 2023
($17.94M)
May 14, 2024